» Articles » PMID: 14707107

Defective Control of Latent Epstein-Barr Virus Infection in Systemic Lupus Erythematosus

Overview
Journal J Immunol
Date 2004 Jan 7
PMID 14707107
Citations 110
Authors
Affiliations
Soon will be listed here.
Abstract

EBV infection is more common in patients with systemic lupus erythematosus (SLE) than in control subjects, suggesting that this virus plays an etiologic role in disease and/or that patients with lupus have impaired EBV-specific immune responses. In the current report we assessed immune responsiveness to EBV in patients with SLE and healthy controls, determining virus-specific T cell responses and EBV viral loads using whole blood recall assays, HLA-A2 tetramers, and real-time quantitative PCR. Patients with SLE had an approximately 40-fold increase in EBV viral loads compared with controls, a finding not explained by disease activity or immunosuppressive medications. The frequency of EBV-specific CD69+ CD4+ T cells producing IFN-gamma was higher in patients with SLE than in controls. By contrast, the frequency of EBV-specific CD69+ CD8+ T cells producing IFN-gamma in patients with SLE appeared lower than that in healthy controls, although this difference was not statistically significant. These findings suggest a role for CD4+ T cells in controlling, and a possible defect in CD8+ T cells in regulating, increased viral loads in lupus. These ideas were supported by correlations between viral loads and EBV-specific T cell responses in lupus patients. EBV viral loads were inversely correlated with the frequency of EBV-specific CD69+ CD4+ T cells producing IFN-gamma and were positively correlated with the frequencies of CD69+ CD8+ T cells producing IFN-gamma and with EBV-specific, HLA-A2 tetramer-positive CD8+ T cells. These results demonstrate that patients with SLE have defective control of latent EBV infection that probably stems from altered T cell responses against EBV.

Citing Articles

Molecular mimicry in the pathogenesis of autoimmune rheumatic diseases.

Fehringer M, Vogl T J Transl Autoimmun. 2025; 10:100269.

PMID: 39877080 PMC: 11773492. DOI: 10.1016/j.jtauto.2025.100269.


Type I interferon and mitochondrial dysfunction are associated with dysregulated cytotoxic CD8+ T cell responses in juvenile systemic lupus erythematosus.

Radziszewska A, Peckham H, Restuadi R, Kartawinata M, Moulding D, de Gruijter N Clin Exp Immunol. 2024; 219(1).

PMID: 39719886 PMC: 11748002. DOI: 10.1093/cei/uxae127.


Autoimmune disease: a view of epigenetics and therapeutic targeting.

Mu S, Wang W, Liu Q, Ke N, Li H, Sun F Front Immunol. 2024; 15:1482728.

PMID: 39606248 PMC: 11599216. DOI: 10.3389/fimmu.2024.1482728.


Infection-Associated Flares in Systemic Lupus Erythematosus.

Ramirez G, Calabrese C, Secci M, Moroni L, Gallina G, Benanti G Pathogens. 2024; 13(11).

PMID: 39599487 PMC: 11597141. DOI: 10.3390/pathogens13110934.


Autologous Epstein-Barr virus-specific adoptive T-cell therapy in a patient with lupus nephritis.

Ranganathan D, Leibowitz S, John G, Neller M, Ambalathingal G, Beagley L Clin Transl Immunology. 2024; 13(11):e70015.

PMID: 39564002 PMC: 11574558. DOI: 10.1002/cti2.70015.